Royalty Pharma plc
corporate_fare Company Profile
Royalty Pharma plc (NASDAQ:RPRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for RPRX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 8/10, with 7 rated 8 or above. Recent SEC coverage for RPRX spans 10-Q, 8-K, SCHEDULE 13D/A, 10-K.
Recent high-impact activity:
- Royalty Pharma Q3: Net Income Halved to $145M on Pelacarsen Impairment; Vertex Royalty Dispute Disclosed
- Royalty Pharma Raises 2026 Portfolio Receipts Guidance to $3.50-$3.55B on 9% Q3 Growth
- Royalty Pharma Posts $145M Third-Quarter Net Income
- Royalty Pharma Commits $100M to Zealand's Rusfertide
- Royalty Pharma Q2 Portfolio Receipts Rise 6%, Full-Year Guidance Raised to $3.4–$3.5 Billion
Financial Snapshot
Short Interest & Short Volume
3.97 days to coverFINRA reported short interest of 13,075,722 shares in RPRX as of the October 30, 2026 settlement, a 1.8% increase from the prior period — about 4.0 days to cover at its recent average daily volume. On November 20, 2026, 59.5% of RPRX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.